Verici Dx (Verici Dx) Pretax Margin %

: -27,752.63% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Verici Dx's Pre-Tax Income for the six months ended in Jun. 2023 was $-5.27 Mil. Verici Dx's Revenue for the six months ended in Jun. 2023 was $0.02 Mil. Therefore, Verici Dx's pretax margin for the quarter that ended in Jun. 2023 was -27,752.63%.

The historical rank and industry rank for Verici Dx's Pretax Margin % or its related term are showing as below:

VRCDF' s Pretax Margin % Range Over the Past 10 Years
Min: -60353.33 Med: 0 Max: 0
Current: -60353.33

VRCDF's Pretax Margin % is ranked worse than
100% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.495 vs VRCDF: -60353.33

Verici Dx Pretax Margin % Historical Data

The historical data trend for Verici Dx's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Pretax Margin %

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Pretax Margin %	-	-	-	-	-27,752.63

Competitive Comparison

For the Diagnostics & Research subindustry, Verici Dx's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx Pretax Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Verici Dx's Pretax Margin % falls into.

Verici Dx Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Verici Dx's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-11.407	/	0
	=	%

Verici Dx's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-5.273	/	0.019
	=	-27,752.63 %

Verici Dx (OTCPK:VRCDF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Verici Dx Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Verici Dx's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines